Table 1.
Patient demographics, liver disease characteristics, and clinical presentation (median and ranges).
| Variables | Overall population (n = 89) | Death (n = 24) | Survival (n = 65) | P value |
|---|---|---|---|---|
| Age (yr) | 59 (30-80) | 59 (40-80) | 58 (30-78) | 0.045 |
| Sex (male/female) | 54/35 | 16/8 | 38/27 | 0.626 |
| Etiology of liver cirrhosis (viral/others) | 50/39 | 15/9 | 35/30 | 0.631 |
| Indication for TIPS1 (bleeding/ascites/both) | 73/4/12 | 17/2/5 | 56/2/7 | 0.764 |
| CTP2 score | 7 (5-10) | 8 (6-10) | 7 (5-10) | 0.019 |
| CTP classification (A/B/C) | 24/62/3 | 4/18/2 | 20/44/1 | 0.147 |
| MELD3 score | 10 (6-21) | 10.5 (7-21) | 10 (6-16) | 0.048 |
| SB4 (μmol/L) | 16.4 (6.3-78.6) | 21.6 (6.8-78.6) | 16.1 (6.3-51.3) | 0.010 |
| PLT5 (×1012/L) | 55 (16-207) | 46.5 (16-116) | 55 (22-207) | 0.348 |
| PT6 (s) | 15.0 (11.5-20.1) | 15.7 (12.5-20.1) | 15.0 (11.5-19.4) | 0.114 |
| ALT7 (IU/L) | 21.0 (5.2-136.7) | 22.5 (5.2-136.7) | 20.3 (6.0-66.2) | 0.857 |
| AST8 (IU/L) | 26.6 (14.0-159.3) | 26.3 (18.8-159.3) | 26.7 (14-80.1) | 0.524 |
| ALB9 (g/L) | 33.1 (19.8-40.0) | 32.2 (23.6-38.9) | 33.5 (19.8-40.0) | 0.482 |
| Cr10 (μmol/L) | 64 (37-269) | 70 (47-269) | 62 (37-144) | 0.157 |
| Mild PVT11 (yes/no) | 13/76 | 3/21 | 10/55 | 1.000 |
| Ascites (no/mild/moderate/large) | 17/36/20/16 | 2/8/7/7 | 15/28/13/9 | 0.148 |
| Liver stiffness (m/s) | 1.96 (1.46-3.39) | 2.08 (1.65-3.39) | 1.92 (1.46-2.99) | 0.025 |
| Spleen stiffness (m/s) | 3.43 (2.82-4.04) | 3.60 (3.20-4.04) | 3.31 (2.82-3.74) | <0.001 |
Data are medians (ranges). 1TIPS: transjugular intrahepatic portosystemic shunt; 2CTP: Child-Turcotte-Pugh; 3MELD: model for end-stage liver disease; 4SB: serum bilirubin; 5PLT: platelet; 6PT: prothrombin time; 7ALT: alanine aminotransferase; 8AST: aspartate aminotransferase; 9ALB: albumin; 10Cr: creatinine; 11PVT: portal vein thrombosis.